MPAM
PMVP icon

Monarch Partners Asset Management’s PMV Pharmaceuticals PMVP Stock Holding History

Monarch Partners Asset Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.29M Buy
263,449
+53,079
+25% +$566K 0.68% 67
2022
Q3 		$2.5M Buy
+210,370
New +$3.04M 0.75% 59

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Monarch Partners Asset Management's PMVP Position: Q4 2022 in Review

Monarch Partners Asset Management increased its PMV Pharmaceuticals (PMVP) stake by 25% in Q4 2022, buying an estimated $566K and bringing the position to 263,449 shares worth $2.29M. The position accounts for 0.68% of the portfolio, ranked #67.

Monarch Partners Asset Management first reported a position in PMVP in Q3 2022 and has held it in 2 quarters since. The position peaked at $2.5M in Q3 2022. 115 funds tracked by Wall St. Rank hold PMVP as of Q4 2022.

  • Monarch Partners Asset Management held 263,449 shares of PMV Pharmaceuticals worth $2.29M as of Q4 2022.
  • Monarch Partners Asset Management bought 53,079 PMV Pharmaceuticals shares in Q4 2022, an estimated $566K.
  • PMV Pharmaceuticals made up 0.68% of Monarch Partners Asset Management's portfolio in Q4 2022, its #67 holding.
  • Monarch Partners Asset Management first reported a position in PMV Pharmaceuticals in Q3 2022 and has held it in 2 quarters since.
  • Monarch Partners Asset Management's PMV Pharmaceuticals position peaked at $2.5M in Q3 2022.
  • 115 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.